NVO sets Nov 14, 2025 EGM; chair and vice chair not standing
Rhea-AI Filing Summary
Novo Nordisk A/S will convene an Extraordinary General Meeting to elect new members of the Board of Directors on 14 November 2025. The decision follows dialogue with the Novo Nordisk Foundation about board composition; the Foundation holds the majority of votes. The Board concluded that electing new members via an EGM is in the best interest of the company and shareholders to provide clarity on future governance.
Chair Helge Lund, Vice Chair Henrik Poulsen, and independent directors Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law and Martin Mackay will not stand for election at the EGM. Kasim Kutay (not independent) and employee‑elected members Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen and Thomas Rantzau will remain on the Board.
Novo Nordisk will host an investor conference call at 15:00 CEST on 21 October 2025, with a dial‑in link available on the company’s investor website.
Positive
- None.
Negative
- None.
Insights
EGM called to reset board; several leaders not standing.
Novo Nordisk is initiating a board refresh via an EGM on
Multiple senior directors, including the Chair and Vice Chair, will not stand for election, while one non‑independent member and employee representatives remain. This points to continuity in employee representation with potential changes in independent oversight, depending on the slate presented in the notice.
Investors get a near‑term milestone via the
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
October 21, 2025
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors
Bagsværd, Denmark, 21 October 2025 - Novo Nordisk today announced that the Board of Directors have decided to convene an Extraordinary General Meeting to elect new members of the Board of Directors of Novo Nordisk.
“Following dialogue with the Novo Nordisk Foundation regarding the future composition of the Board of Directors, it has not been possible to reach a common understanding. The Board proposed a renewal focusing on addition of select, new competencies while also maintaining continuity, whereas the Board of the Foundation wanted a more extensive reconfiguration. After thorough deliberation and considering the Foundation’s position and control of the majority of votes in Novo Nordisk, the Board concluded that it is in the best interest of the company and its shareholders to convene an Extraordinary General Meeting to elect new board members to provide clarity on the future governance of Novo Nordisk,” said Chair of the Board of Directors of Novo Nordisk, Helge Lund.
Chair Helge Lund, Vice Chair Henrik Poulsen and the independent board members Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law and Martin Mackay will not stand for election at the Extraordinary General Meeting. Kasim Kutay (not independent) and the employee elected board members Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen and Thomas Rantzau will remain on the Board.
The Extraordinary General Meeting will be convened to be held on 14 November 2025. The notice will be issued in a separate company announcement today.
Reference is made to the Novo Nordisk Foundation’s press release.
Page 2 of 2
Conference call
Novo Nordisk will host a conference call for investors at 15.00 CEST on 21 October 2025, corresponding to 9:00 am EDT. A dial-in link to the conference call will be published on the investor section of novonordisk.com.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. As of August 2025, Novo Nordisk employed about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Publication of inside information pursuant to Market Abuse Regulation, Article 17.
Contacts for further information
| Media: | ||
| Ambre James-Brown | Liz Skrbkova (US) | |
| +45 3079 9289 | +1 609 917 0632 | |
| abmo@novonordisk.com | lzsk@novonordisk.com | |
| Investors: | ||
| Jacob Martin Wiborg Rode | Sina Meyer | |
| +45 3075 5956 | +45 3079 6656 | |
| jrde@novonordisk.com | azey@novonordisk.com | |
| Christoffer Sho Togo Tullin | Alex Bruce | Frederik Taylor Pitter |
| +45 3079 1471 | +45 3444 2613 | +1 609 613 0568 |
| cftu@novonordisk.com | axeu@novonordisk.com | fptr@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 28 / 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: October 21, 2025 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |
